Secarna Pharmaceuticals and Curie.Bio expand existing partnership
Lucy Batizovsky | March 6, 2026 | News story | Research and Development | Curie.Bio, Secarna Pharmaceuticals, partnership
Secarna Pharmaceuticals has announced the expansion of the existing scientific and strategic collaboration agreement with Curie.Bio.
The collaboration, first announced in May 2025, now includes Secarna’s support in identifying oligonucleotide candidates using its proprietary OligoCreator platform for R&D projects conducted by Curie.Bio portfolio companies.
Secarna’s AI-empowered OligoCreator platform integrates diverse delivery technologies as well as proprietary safety and efficacy testing systems to identify and characterise oligonucleotide therapeutics.
Konstantin Petropoulos, CEO of Secarna Pharmaceuticals, said: “The decision to expand our cooperation serves as validation of our fruitful partnership with Curie.Bio so far.”
Secarna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of oligonucleotide therapeutics, offering hope to patients facing conditions that are beyond the reach of current approaches and modalities.
Curie.Bio, a global venture capital firm, helps founders discover and develop new medicines. Their model combines capital with hands-on drug development, operating as both a drug discovery copilot and an investor.
“Our shared vision of transforming scientific innovation into life-changing therapies guides our daily work, driving us to efficiently generate measurable results in discovering and developing best-in-class drug products,” Petropoulos added.
Related Content
Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration …
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics …
